Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.